Loss of Jmjd6 significantly impacts recovery from hematopoietic injury. (A) Experimental design. Eight- to 12-week-old Jmjd6^cKO and Jmjd6^CTL mice were administered 1 dose of 5-FU (250 mg/kg) via IV injection, and hematopoietic compartments were analyzed 10 and 14 days later. (B) Total BM cellularity (1 femur and 1 tibia) of 5-FU–treated Jmjd6^cKO and Jmjd6^CTL mice (n = 4-7) and Jmjd6^CTL PBS-treated controls (n = 2) at 10 and 14 days postinjection. Total cell numbers of B cells and myeloid cells (C), LK cells (D), LSK cells (E), and HSCs, MPPs, and HPC-1 and HPC-2 populations (F) in BM from Jmjd6^cKO and Jmjd6^CTL mice 10 and 14 days following 5-FU treatment (n = 4-7). (G) Representative FACS profiles showing frequencies (± SEM) of BM LSK, HSC, MPP, HPC-1, and HPC-2 cell populations from 5-FU–treated Jmjd6^cKO and Jmjd6^CTL mice (n = 4-7) and Jmjd6^CTL PBS-treated controls (n = 2) at 10 and 14 days postinjection. Data are mean ± SEM. *P < .05, **P < .01, Mann-Whitney U test.